Stocks · News reference
Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $101.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-28 AccNo: 0001099800-26-000048 Size: 137 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $105.
Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue. EW stock jumps as analysts see continued upside ahead.